{"name": "Logical Therapeutics",
 "permalink": "logical-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/logical-therapeutics",
 "homepage_url": "http://www.logicaltx.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2005,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@logicaltx.com",
 "phone_number": "781-290-0900",
 "description": "",
 "created_at": "Tue May 25 03:45:57 UTC 2010",
 "updated_at": "Fri May 28 03:52:06 UTC 2010",
 "overview": "\u003Cp\u003ELogical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       33],
      "assets/images/resized/0008/8366/88366v1-max-150x150.jpg"],
     [[250,
       55],
      "assets/images/resized/0008/8366/88366v1-max-250x250.jpg"],
     [[354,
       79],
      "assets/images/resized/0008/8366/88366v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Peter",
      "last_name": "A. Lankau",
      "permalink": "peter-a-lankau",
      "image":
       {"available_sizes":
         [[[100,
            100],
           "assets/images/resized/0025/4510/254510v1-max-150x150.jpg"],
          [[100,
            100],
           "assets/images/resized/0025/4510/254510v1-max-250x250.jpg"],
          [[100,
            100],
           "assets/images/resized/0025/4510/254510v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Carolyn",
      "last_name": "E. Green",
      "permalink": "carolyn-e-green",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$16.9M",
 "funding_rounds":
  [{"round_code": "c",
    "source_url": "http://www.fiercebiotech.com/story/logical-therapeutics-closes-16-9m-round-nsaid-program/2010-05-27?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Logical Therapeutics closes $16.9M round for NSAID program",
    "raised_amount": 16900000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 5,
    "funded_day": 27,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "SV Life Sciences",
         "permalink": "sv-life-sciences",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0004/5361/45361v2-max-150x150.png"],
             [[250,
               84],
              "assets/images/resized/0004/5361/45361v2-max-250x250.png"],
             [[332,
               112],
              "assets/images/resized/0004/5361/45361v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novo A/S",
         "permalink": "novo-a-s",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0025/1103/251103v1-max-150x150.png"],
             [[250,
               99],
              "assets/images/resized/0025/1103/251103v1-max-250x250.png"],
             [[250,
               99],
              "assets/images/resized/0025/1103/251103v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novitas Capital",
         "permalink": "novitas-capital",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0000/3478/3478v2-max-150x150.png"],
             [[200,
               26],
              "assets/images/resized/0000/3478/3478v2-max-250x250.png"],
             [[200,
               26],
              "assets/images/resized/0000/3478/3478v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "300 Second Avenue",
    "address2": "",
    "zip_code": "02451",
    "city": "Waltham",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        79],
       "assets/images/resized/0008/8365/88365v1-max-150x150.jpg"],
      [[250,
        132],
       "assets/images/resized/0008/8365/88365v1-max-250x250.jpg"],
      [[450,
        238],
       "assets/images/resized/0008/8365/88365v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}